Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
Nephron ; 2024 Feb 09.
Article in English | MEDLINE | ID: mdl-38342092

ABSTRACT

INTRODUCTION: To explore the association between urate-lowering agents and reduced response to erythropoietin-stimulating agents in patients suffering from chronic kidney disease G5. METHODS: We conducted a cross-sectional, multicenter study in Japan between April and June 2013, enrolling patients aged 20 years or older with an estimated glomerular filtration rate of ≤15 mL/min/1.73 m2. Exclusion criteria encompassed patients with a history of hemodialysis, peritoneal dialysis, or organ transplantation. The patients were categorized into four groups based on the use of urate-lowering drugs: high-dose allopurinol (>50 mg/day), low-dose allopurinol (≤50 mg/day), febuxostat, and no-treatment groups. We used a multivariable logistic regression model, adjusted for covariates, to determine the odds ratio (OR) for erythropoietin hyporesponsiveness, defined by an erythropoietin resistance index (ERI) of ≥10, associated with urate-lowering drugs. RESULTS: A total of 542 patients were included in the analysis, with 105, 36, 165, and 236 patients in the high-dose allopurinol, low-dose allopurinol, febuxostat, and no-treatment groups, respectively. The median and quartiles of ERIs were 6.3 (0, 12.2), 3.8 (0, 11.2), 3.4 (0, 9.8), and 4.8 (0, 11.2) in the high-dose allopurinol, low-dose allopurinol, febuxostat, and no-treatment groups, respectively. The multivariate regression model showed a statistically significant association between the high-dose allopurinol group and erythropoietin hyporesponsiveness, compared to the no-treatment group (OR=1.98, 95% confidence interval: 1.10-3.57). CONCLUSIONS: Our study suggests that the use of high-dose allopurinol exceeding the optimal dose may lead to hyporesponsiveness to erythropoiesis-stimulating agents.

2.
Intern Med ; 58(14): 2057-2061, 2019 Jul 15.
Article in English | MEDLINE | ID: mdl-30918180

ABSTRACT

Several case series have suggested that rituximab is efficacious in adult patients with minimal change disease. We herein report a case of disseminated intravascular coagulation-like reaction after rituximab infusion in a patient with nephrotic syndrome. A 58-year-old Japanese man with minimal change disease diagnosed 15 years earlier was started on rituximab to prevent relapse of nephrotic syndrome when he presented to our clinic with low albuminemia, massive proteinuria, and leg edema. Eleven days after rituximab infusion, he presented with abdominal pain, appetite loss, and tarry stool. A laboratory examination revealed severe thrombocytopenia and coagulopathy, and upper gastrointestinal endoscopy revealed multiple hemorrhagic ulcers in his esophagus and stomach. The patient died two days later. Physicians should consider disseminated intravascular coagulation-like reaction when encountering cases with thrombocytopenia after rituximab infusion for any disease.


Subject(s)
Disseminated Intravascular Coagulation/chemically induced , Disseminated Intravascular Coagulation/mortality , Nephrotic Syndrome/drug therapy , Rituximab/adverse effects , Rituximab/therapeutic use , Thrombocytopenia/chemically induced , Thrombocytopenia/mortality , Disseminated Intravascular Coagulation/diagnosis , Fatal Outcome , Humans , Japan , Male , Middle Aged
3.
Shinrigaku Kenkyu ; 86(6): 577-83, 2016 Feb.
Article in Japanese | MEDLINE | ID: mdl-26964372

ABSTRACT

The present study revised a psycho-educational program designed to prevent depression (Oikawa & Sakamoto, 2007) and to enhance interpersonal coping resources for depression. The effects of the revised program on female undergraduates were examined. One hundred and seventy two udergraduates were assigned either to an experimental group or a control group. The experimental group participated in the revised program for ten weeks as part of a psychological class, while the control group did not. All participants were asked to complete a self-report questionnaire about self-efficacy for cognitive, behavioral, and interpersonal coping for depression, the state of their mental health, and perceived social support from their family and friends before and after the program. The experimental group's ratings and responses indicated that the program were interesting and meaningful. Moreover, self-efficacy for coping with depression and perceived support from friends at the post intervention were significantly increased in the experimental group compared with the control group. These results suggest the effectiveness of the revised program for increasing interpersonal coping resources.


Subject(s)
Depression/prevention & control , Students/psychology , Adaptation, Psychological , Female , Humans , Self Efficacy , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...